May. 13 at 8:33 PM
$LGVN
🚨🚨🚨
Longeveron Inc. reported first quarter 2026 results and outlined a shift to a more capital-efficient, asset-light model focused on partnering its stem cell therapy laromestrocel across four programs.
For the quarter ended March 31, 2026, revenue was
$398,000, slightly above
$381,000 a year earlier, driven mainly by clinical trial revenue.
The company posted a net loss of
$4.7 million, modestly improved from a
$5.0 million loss in 2025, with operating expenses of
$5.0 million
Basic and diluted net loss per share was
$0.19 on 24.8 million weighted average shares
Cash and cash equivalents rose to
$15.8 million from
$4.7 million at December 31, 2025, increasing total assets to
$21.2 million
Longeveron highlighted upcoming catalysts, including top-line Phase 2b results in Hypoplastic Left Heart Syndrome expected in August 2026, and described an active partnering strategy targeting HLHS, Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging-related frailty.
